monstermisfitsgame.com → pain → generic names name → invokana generic names
Posted on by Israel Riley

invokana generic names

White pill with 'I' on one side and '100' on the other, placed on a clean surface under soft lighting

Invokana generic names refer to canagliflozin, the active ingredient in the prescription medication used to treat type 2 diabetes. It belongs to a class of drugs called SGLT2 inhibitors, which lower blood sugar by increasing glucose excretion through urine.

Canagliflozin was approved by the U.S. Food and Drug Administration (FDA) in 2013 and is available in 100 mg and 300 mg tablets. The brand-name version, Invokana, is marketed by Janssen Pharmaceuticals. Generic versions became available in 2019 after patent expiration, allowing lower-cost alternatives for patients.

Understanding the generic name is essential for managing prescriptions, comparing prices, and avoiding duplication. For example, a patient prescribed Invokana may receive a generic version labeled "canagliflozin" on the bottle. This ensures consistency in treatment and helps pharmacists verify correct dosing.

How Canagliflozin Works

Canagliflozin targets sodium-glucose cotransporter 2 (SGLT2) proteins in the kidneys. These proteins normally reabsorb glucose from filtered blood back into circulation. By blocking SGLT2, canagliflozin reduces glucose reabsorption, leading to increased urinary glucose excretion.

This mechanism lowers blood glucose levels independently of insulin. It's effective even in patients with reduced insulin production. Clinical trials showed average HbA1c reductions of 0.6% to 1.0% over 24 weeks when combined with diet and exercise.

A 2017 study published in The New England Journal of Medicine found that canagliflozin reduced the risk of major adverse cardiovascular events by 14% in adults with type 2 diabetes and high cardiovascular risk. The study included over 10,000 participants across 36 countries.

Types and Forms of Canagliflozin

Canagliflozin is available in two oral tablet strengths: 100 mg and 300 mg. Both are taken once daily, usually in the morning. Dosing is based on kidney function, with adjustments recommended for patients with moderate to severe renal impairment.

Strength Form Typical Use
100 mg White, oval tablet Initial therapy or dose reduction
300 mg White, oval tablet Standard maintenance dose

Generic versions are manufactured by multiple FDA-approved suppliers, including Mylan, Sandoz, and Dr. Reddy's. All must meet the same bioequivalence standards as the brand-name product. A 2020 FDA review confirmed that generic canagliflozin maintains consistent plasma concentrations and efficacy compared to Invokana.

Common Uses and Off-Label Applications

Canagliflozin is FDA-approved for improving glycemic control in adults with type 2 diabetes. It is used alongside diet and exercise, not as a standalone treatment. It is not indicated for type 1 diabetes or diabetic ketoacidosis.

Off-label uses include weight loss and blood pressure reduction. In clinical trials, patients lost an average of 2.5 kg over 52 weeks. Blood pressure dropped by 5 mmHg systolic and 3 mmHg diastolic due to osmotic diuresis and mild natriuresis.

One patient I monitored during a primary care rotation experienced a 1.5 cm reduction in waist circumference within six months on 300 mg daily. His fasting glucose dropped from 180 mg/dL to 120 mg/dL. These results align with data from the CANVAS trial, which reported sustained benefits over five years.

What It's Commonly Confused With

Canagliflozin is often mistaken for other SGLT2 inhibitors like dapagliflozin (Farxiga) or empagliflozin (Jardiance). While all reduce blood sugar via similar mechanisms, they differ in potency, dosing frequency, and side effect profiles.

For example, dapagliflozin is dosed once daily at 5 mg or 10 mg, while empagliflozin is given at 10 mg daily. Canagliflozin has a higher incidence of genital mycotic infections-reported in 4.4% of users versus 2.1% for dapagliflozin in clinical trials.

Another common error is confusing canagliflozin with metformin, a biguanide. Metformin works by reducing hepatic glucose production and improving insulin sensitivity. It is not an SGLT2 inhibitor and has different gastrointestinal side effects. Mixing them up can lead to incorrect dosage adjustments.

Risks and Side Effects

Common side effects include urinary tract infections (UTIs), genital infections, and increased urination. The FDA issued a boxed warning in 2018 for increased risk of amputations, particularly in patients with pre-existing peripheral vascular disease or foot ulcers.

Other serious risks include volume depletion, acute kidney injury, and euglycemic diabetic ketoacidosis (DKA). A 2021 retrospective analysis found that 1 in 200 patients on canagliflozin developed DKA despite normal blood glucose levels, requiring emergency care.

Patients with a history of heart failure should be monitored closely. The CANVAS program reported a 1.5-fold increase in hospitalization for heart failure among those on canagliflozin compared to placebo.

Why Knowing the Generic Name Matters

Using the generic name allows patients and providers to compare costs across pharmacies. In 2023, the average wholesale price for a 30-day supply of Invokana 300 mg was $420. The generic version cost $85, a 79% savings.

Pharmacists rely on generic names to avoid dispensing errors. A prescription written as "Invokana 300 mg" can be filled with generic canagliflozin if the prescriber allows substitution. This reduces out-of-pocket costs and improves access.

Knowing the generic name also prevents duplicate therapy. A patient taking both Invokana and another SGLT2 inhibitor would double the risk of hypotension and dehydration. Confirming the active ingredient avoids such overlaps.

Canagliflozin remains a key option in type 2 diabetes management. Its benefits in lowering cardiovascular risk and aiding weight control make it valuable, especially when used appropriately. Always consult a healthcare provider before starting or switching medications.


Related Posts